Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Penetration of BV100 (Intravenous Rifabutin) in Healthy Participants
NCT05684705Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BV100 in Acinetobacter baumannii infection, sponsored by BioVersys AG. Primary endpoints: Plasma concentration of rifabutin at 5 days, Epithelial lining fluid concentration of rifabutin at 5 days and 1 more. Started Sep 2023; status: completed.
02
Drugs
BV100
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT05684705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684705.